<DOC>
	<DOCNO>NCT01670266</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability 3 planned dos ONO-9054 eye adult male female patient ocular hypertension ( OHT ) mild open angle-glaucoma ( OAG ) . The secondary objective evaluate Pharmacodynamics ( PD ) characterize pharmacokinetic ( PK ) profile ONO-9054 metabolite plasma compare tolerability follow morning even dosing .</brief_summary>
	<brief_title>Single Multiple Dose Escalation Two-sequence Crossover Study ONO-9054 Patients With Ocular Hypertension Mild Open-angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Male female subject age 1880 ( inclusive ) confirm diagnosis OHT OAG Confirmed diagnosis bilateral OHT chronic openangle glaucoma Able undergo washout ocular drug An IOP ≥ 22mmHg 8:00 AM ≥ 21 mmHg 10:00 AM least one eye ; ≤ 35 mmHg time point eye Day 2 Day 1 Central corneal thickness 500600 µm screen eye BCVA 20/100 well eye Any history severe ocular trauma either eye time Any history previous intraocular ocular laser surgery within past 3 month refractive surgery procedure within past 6 month screen visit study eye ( ) Cataracts prevent observation fundus either eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>ONO-9054</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>OHT</keyword>
	<keyword>Open angle-glaucoma</keyword>
	<keyword>OAG</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Eye disease</keyword>
</DOC>